NRXS · XBRL financial data
Neuraxis financial statements, every fiscal year
The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NRXS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Revenue | 2,460 | 2,686 | 3,569 |
| Revenue from contracts with customers | 2,460 | 2,686 | 3,569 |
| Cost of goods and services sold | 303 | 362 | 563 |
| Gross profit | 2,157 | 2,324 | 3,006 |
| Research and development | 169 | 206 | 494 |
| General and administrative | 8,328 | 8,950 | 8,063 |
| Operating income (loss) | (6,664) | (7,157) | (7,830) |
| Interest expense | 476 | 174 | 74 |
| Other income (expense) | (7,962) | (1,085) | 29 |
| Net income (loss) | (14,627) | (8,242) | (7,801) |
| Earnings per share, basic USD per share | (4.50) | (1.22) | (0.95) |
| Earnings per share, diluted USD per share | (4.50) | (1.22) | (0.95) |
| Weighted average shares, basic thousands of shares | 3,252 | 6,919 | 9,083 |
| Weighted average shares, diluted thousands of shares | 3,252 | 6,919 | 9,083 |
Balance sheet
CSVFiscal years (NRXS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 79 | 3,697 | 4,965 |
| Accounts receivable | 73 | 245 | 196 |
| Inventory | 21 | 44 | 257 |
| Prepaid and other current assets | 70 | 280 | 315 |
| Total current assets | 243 | 4,266 | 5,733 |
| Property and equipment, net | 89 | 90 | 76 |
| Right-of-use asset | 70 | 285 | 262 |
| Total assets | 509 | 4,758 | 6,404 |
| Accounts payable | 1,204 | 597 | 139 |
| Accrued liabilities | 401 | 1,578 | 2,393 |
| Total current liabilities | 1,886 | 2,433 | 2,792 |
| Total deposits | 75 | 33 | 29 |
| Lease liability, non-current | 27 | 256 | 203 |
| Total liabilities | 1,913 | 2,690 | 3,005 |
| Accumulated deficit | (48,558) | (56,800) | (64,600) |
| Total stockholders' equity | (1,403) | 2,068 | 3,399 |
| Total liabilities and equity | 509 | 4,758 | 6,404 |
| Common shares outstanding (cover page) thousands of shares | 6,595 | 6,648 | 11,188 |
Cash flows
CSVFiscal years (NRXS's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (14,627) | (8,242) | (7,801) |
| Stock-based compensation | 0 | 227 | 597 |
| Depreciation and amortization | 41 | 38 | — |
| Net cash from operating activities | (6,694) | (6,098) | (6,433) |
| Purchases of property and equipment | 31 | 28 | 31 |
| Net cash from investing activities | (72) | (28) | (131) |
| Proceeds from issuing common stock | 4,847 | — | 7,728 |
| Net cash from financing activities | 6,591 | 9,744 | 7,832 |
| Net change in cash | (175) | 3,618 | 1,268 |
Compare with peers
SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Neuraxis | 8,322 | 1,929 | (1,030)* | 12.6M | — | 10-QJun 30, 2026 |
| Allurion Technologies | 5,056 | 2,947 | (3,221) | 15.0M | 1.6 quarters | 10-QMar 31, 2026 |
| Dror Ortho-Design | 94 | not reported | (305)* | 977.0M | 0.3 quarters | 10-QJun 30, 2026 |
| Positron | 357 | 112 | (1,050)* | 32.8M | 0.3 quarters | 10-QJun 30, 2026 |
| Vivos Therapeutics | 1,774 | 5,153 | (3,148)* | 20.1M | 0.6 quarters | 10-QJun 30, 2026 |
| United Health Products | 24 | 0 | (138)* | 262.7M | 0.2 quarters | 10-QJun 30, 2026 |
| Neuroone Medical Technologies | 2,048 | 1,973 | (1,082)* | 9.1M | 1.9 quarters | 10-QJun 30, 2026 |
| Precision Optics | 9,841 | 8,774* | (649)* | 11.0M | 15.2 quarters | 10-KJun 30, 2026 |
| Encision | 72 | 1,528 | (127)* | 16.9M | 0.6 quarters | 10-QSep 30, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.